Business Wire

RUBICON-CAPITAL-ADVISORS

14.1.2022 12:52:09 CET | Business Wire | Press release

Share
Rubicon Advises Elgin Energy on the Sale of the UK’s Largest Portfolio of Solar PV Projects

Rubicon Capital Advisors (“Rubicon”), one of the world’s leading investment banking firms focused on the broader infrastructure, energy and digital sectors, announced its role as exclusive sell-side financial advisor to Elgin Energy Holdings (“Elgin”) in reaching completion on the 100% sale of a 519 MW portfolio of solar PV projects and 70 MW of co-located energy storage capacity (the “Portfolio”) to ScottishPower Renewables (UK) Limited (“Scottish Power”), a wholly-owned subsidiary of global utility Iberdrola Group.

The portfolio sale marks the UK’s largest solar PV transaction to date, consisting of 12 projects at the pre-construction stage located across England, Wales and Scotland, with a combined capacity of 519MW. The portfolio also includes a co-located 70MW battery solution that is at an advanced stage of development.

“We are delighted to have reached this significant milestone and partnered with Iberdrola / ScottishPower Renewables on this portfolio. We will continue to develop and deliver on our 5GW project pipeline across the UK, Ireland and Australia, working closely with landowners, local authorities and all related stakeholders”, commented Ronan Kilduff, CEO of Elgin Energy.

The portfolio will play a pivotal role in contributing towards the UK’s 2050 Net Zero Strategy, not only generating low cost and low carbon electricity but also creating significant regional economic development and supplying zero-carbon electricity to over 143,000 homes across the UK.

“We have a proven track record in working with global developers and large renewable energy portfolios of scale across the world and we are delighted to have advised on the UK’s largest solar and storage transaction to date. This is a landmark transaction on many fronts, representing a new frontier in the UK and internationally in terms of both scales and in combining solar PV and large-scale battery storage into a single asset portfolio. Moreover, this transaction is an excellent example of Rubicon’s commitment to be at the leading edge of ESG initiatives, particularly as they relate to tackling global climate change issues”, commented Barry O’Flynn, Managing Director at Rubicon.

About Rubicon Capital Advisors

Rubicon is one of the world’s leading investment banking firms focused solely on the infrastructure, energy, digital & utilities sectors. With offices in Europe, the Americas and Asia, the firm has a truly global reach. Since its inception in 2011, Rubicon has closed on the sale, acquisition or refinancing of well over 100 essential infrastructure, energy, digital & utilities assets located across Europe, North America, Latin America and Asia with a combined enterprise value in excess of $85 billion. The firm is regulated by the Central Bank of Ireland and its U.S. affiliate is a member of FINRA and SIPC and registered as a broker-dealer with the SEC. Learn more about the firm at: www.rubiconcapitaladvisors.com and by following Rubicon Capital Advisors on LinkedIn .

About Elgin Energy

Elgin Energy is a full service, utility-scale, solar+storage developer bringing projects from origination through development. The company has a portfolio of projects in late-stage development totalling over 5GW across three key markets of the UK, Australia and Ireland.

In 2021, Elgin Energy secured financing with Berenberg Green Energy Fund for the development of solar PV projects totalling 1.36GW in the UK and Ireland and also raised £25 million via Focus Capital Partners to fund its growth strategy across its core markets. In 2020, the company partnered, in separate transactions, with both Foresight Group and Metka-EGN in relation to two portfolios to deliver a total of 276MW of UK solar development projects and was successful with two Irish solar projects in Ireland’s first solar auction, RESS-1 - Renewable Energy Support Scheme (RESS). In addition to the above, Elgin Energy delivered 21 solar projects, totalling 230MW, before the UK Government’s Renewables Obligation (ROCs) scheme ended in 2017.

Elgin Energy works with long-term strategic partners to deliver projects to energisation and provides asset management services through their operational life. The company has expanded internationally over the last 12 years with a professional team of engineers, accountants and lawyers located in its London, Dublin and Sydney offices. Elgin has a 98% success rate through planning across all its markets.

www.elgin-energy.com & Elgin Energy: Overview | LinkedIn

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye